PANews, June 3 - According to an announcement from Neuralink, the company has completed a $650 million Series E financing round, with investors including ARK Invest, DFJ Growth, Founders Fund, G42, Human Capital, Lightspeed, Qatar Investment Authority (QIA), Sequoia Capital, Thrive Capital, Valor Equity Partners, and Vy Capital. The funding will accelerate clinical trials and product development of its brain-machine interface technology, aimed at restoring autonomy for individuals with paralysis, speech, or vision impairments. Neuralink currently has 5 severely paralyzed patients using its devices to control devices through thought, and has launched clinical trials at several top medical institutions globally.
